EI
TPST icon

EAM Investors’s Tempest Therapeutics TPST Stock Holding History

EAM Investors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,792
Closed -$617K – 333
2023
Q4 		$617K Buy
+10,792
New +$511K 0.11% 212
2015
Q1 		– Sell
-8
Closed -$982K – 396
2014
Q4 		$982K Buy
+8
New +$586K 0.14% 292

Other funds holding TPST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EAM Investors's TPST Position: Q1 2024 in Review

EAM Investors sold out of Tempest Therapeutics (TPST) in Q1 2024, closing a stake of 10,792 shares — an estimated $617K sold.

EAM Investors first reported a position in TPST in Q4 2014 and held it in 2 quarters. The position peaked at $982K in Q4 2014. 28 funds tracked by Wall St. Rank hold TPST as of Q1 2024.

  • EAM Investors reported no remaining Tempest Therapeutics position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 10,792 Tempest Therapeutics shares in Q1 2024, an estimated $617K.
  • EAM Investors first reported a position in Tempest Therapeutics in Q4 2014 and held it in 2 quarters.
  • EAM Investors's Tempest Therapeutics position peaked at $982K in Q4 2014.
  • 28 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.